0001209191-23-010122.txt : 20230216 0001209191-23-010122.hdr.sgml : 20230216 20230216170024 ACCESSION NUMBER: 0001209191-23-010122 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230216 DATE AS OF CHANGE: 20230216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MacLean Michael F CENTRAL INDEX KEY: 0001383731 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 23639232 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-14 0 0001840574 Verve Therapeutics, Inc. VERV 0001383731 MacLean Michael F C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 1 0 0 0 Stock Option (right to buy) 21.76 2023-02-14 4 A 0 7000 0.00 A 2033-02-13 Common Stock 7000 7000 D This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. The shares of common stock underlying the option are scheduled to vest in full upon the one-year anniversary of the grant date, subject to the Reporting Person's continued service. /s/ Andrew Ashe, as Attorney-in-Fact for Michael MacLean 2023-02-16